To evaluate the immunogenicity and safety of an inactivated H@N@ vaccine with and without AS@ adjuvant , as well as mixed vaccine schedules that included sequential administration of AS@ - and MF@-containing formulations and of adjuvanted and unadjuvanted formulations .